Bibliographic citations
Zuñiga, D., (2024). Eficacia y seguridad del tolvaptán vs placebo en pacientes con hiponatremia asociada al síndrome de secreción inapropiada de hormona antidiurética (SIADH): Una Revisión sistemática y Metaanálisis [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/47971
Zuñiga, D., Eficacia y seguridad del tolvaptán vs placebo en pacientes con hiponatremia asociada al síndrome de secreción inapropiada de hormona antidiurética (SIADH): Una Revisión sistemática y Metaanálisis [Tesis]. PE: Universidad Privada Antenor Orrego; 2024. https://hdl.handle.net/20.500.12759/47971
@phdthesis{renati/1355038,
title = "Eficacia y seguridad del tolvaptán vs placebo en pacientes con hiponatremia asociada al síndrome de secreción inapropiada de hormona antidiurética (SIADH): Una Revisión sistemática y Metaanálisis",
author = "Zuñiga Baca, Dalmiro",
publisher = "Universidad Privada Antenor Orrego",
year = "2024"
}
To determine whether tolvaptan is more effective and safer than placebo in increasing sodium levels in patients with hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH). Methods: A systematic review of randomized clinical trials was conducted. Studies comparing tolvaptan and placebo in patients with SIADH-related hyponatremia were included. Early and late response rates, adverse effects, and mortality were evaluated. Results: Seven randomized clinical trials were included in the analysis. Tolvaptan was shown to be more effective than placebo in increasing sodium levels both in early response (RR = 4.35, 95% CI [3-6.30]) and late response (RR = 2.80, 95% CI [1.80- 4.36]). However, a higher risk of adverse effects was observed with tolvaptan (RR = 1.40, 95% CI [1.03-1.89]). There were no significant differences in mortality between the groups (RR = 0.80, 95% CI [0.16-3.96]). Conclusion: Tolvaptan is more effective than placebo in increasing sodium levels in patients with SIADH-related hyponatremia, both in early and late response. However, its use is associated with a higher risk of adverse effects, although no significant differences in mortality were observed
This item is licensed under a Creative Commons License